Details:

Alternative Title:
MMWR. Morbidity and mortality weekly report
Corporate Authors:
United States. Advisory Committee on Immunization Practices. ;
Description:
On February 19, 2010, the Food and Drug Administration (FDA) licensed a quadrivalent meningococcal conjugate vaccine, MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics). MenACWY-CRM is licensed as a single dose for use among persons aged 11-55 years. The Advisory Committee on Immunization Practices (ACIP) reviewed data from prelicensure clinical trials on the safety and immunogenicity of MenACWY-CRM. This report summarizes the approved indications for MenACWY-CRM and provides guidance from ACIP for its use. The following guidance for use of MenACWY-CRM is consistent with licensed indications and ACIP recommendations for meningococcal conjugate vaccines.
Subject:
[+]
Adolescent
Adult
Child
Child, Preschool
Humans
Immunization Schedule
Licensure
Meningococcal Infections
Meningococcal Vaccines
Middle Aged
Neisseria Meningitidis
Risk Factors
Vaccines, Conjugate

Source:
MMWR. Morbidity and mortality weekly report. 2010; 59(9):273.
Pubmed ID:
20224545
Place as Subject:
United States ;
Collection(s):
Guidelines and Recommendations
Morbidity and Mortality Weekly Report (MMWR)
Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:
[+]
urn:sha256:90fbe224a8b74ae1c07903d7ea64a49b3310b5cc69d227d1a1166351d91443e1
File Type:

Supporting Files

• No Additional Files

More +